AR074499A1 - Carboxamidas heterobiciclicas como inhibidoras de cinasas - Google Patents
Carboxamidas heterobiciclicas como inhibidoras de cinasasInfo
- Publication number
- AR074499A1 AR074499A1 ARP090104731A ARP090104731A AR074499A1 AR 074499 A1 AR074499 A1 AR 074499A1 AR P090104731 A ARP090104731 A AR P090104731A AR P090104731 A ARP090104731 A AR P090104731A AR 074499 A1 AR074499 A1 AR 074499A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- hydrogen
- mono
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Composiciones farmacéuticas que comprenden un compuesto de la fórmula (1), y al uso de un compuesto de la fórmula (1) para la preparación de composiciones farmacéuticas para utilizarse en el tratamiento de enfermedades dependientes de la cinasa de proteína, en especial de enfermedades proliferativas, tal como en el tratamiento de enfermedades tumorales y enfermedades neovasculares oculares. Reivindicación 1: Un compuesto de la fórmula (1) o una sal del mismo, en donde R1 es hidrógeno o alquilo C1-6; R2 es hidrógeno o alquilo C1-6; R3 es hidrógeno o alquilo C1-6; R4 es hidrógeno o alquilo C1-6; o R2 y R4, tomados en combinación, forman un enlace; R5 es hidrógeno, alquilo C1-6, o halógeno; R6 representa 0, 1 o 2 residuos independientemente seleccionados en cada presentación a partir de halógeno, o alquilo C1-6; R7 es hidrógeno o alquilo C1-6; X es O o S; Z1 y Z2 se seleccionan independientemente a partir del grupo que consiste en N y CR8; R8 y R10 se seleccionan independientemente a partir del grupo que consiste en hidrógeno y alquilo C1-6; R9 se selecciona a partir del grupo que consisto en (CR11R12)nNR13R14, (CR11R12)nheterociclo, (CR11R12)nOR15, (CR11R12)nC(O)ER13, y (CR11R12)nS(O)mR17; o R8 y R9, tomados en combinación, junto con los átomos con los que están unidos, forman un anillo heterocíclico saturado de 4 a 7 miembros que tiene 1 ó 2 heteroátomos del anillo seleccionados a partir de N, O o S, cuyo anillo heterocíclico está sustituido con 0, 1 o 2 residuos seleccionados independientemente a partir del grupo que consiste en oxo, alquilo C1-6, halo-alquilo C1-6, alcoxilo C1-6, halo-alcoxilo C1-6, halógeno, hidroxilo, amino, hidroxi-alquilo C1-6, amino-alquilo C1-6, mono- y di-alquilo C1-6-amino-alquilo C1-6, cicloalquilo C3-7-alquilo C1-4, hetero-cicloalquilo C1-4, alcanoílo C1-6, mono- y di-alquilo C1-6-amino, amino-carbonilo, mono- y di-alquilo C1-6-amino-carbonilo, alcoxilo C1-6-carbonilo, alquilo C1-6-sulfonilo, amino-sulfonilo, y mono- y di-alquilo C1-6-amino-sulfonilo; Ar2 se selecciona a partir del grupo que consiste en fenilo, naftilo, un heteroarilo monocíclico o bicíclico, y heterociclo bicíclico o tricíclico, en donde cada residuo de heteroarilo o heterociclo tiene 1, 2, 3 o 4 heteroátomos del anillo seleccionados a partir de N, O o S, y en donde el grupo fenilo, naftilo, heteroarilo o heterociclo está insustituido o sustituido por 1, 2, o 3 grupos independientemente seleccionados a partir de alquilo C1-8, halo-alquilo C1-8, hidroxi-alquilo C1-6, alcoxilo C1-8, halo-alcoxilo C1-8, halógeno, hidroxilo, amino, amino-alquilo C1-6, mono- y di-alquilo C1-6-amino-alquilo C1-6, mono- y di-alquilo C1-6-amino, CO2-alquilo C1-6, fenil-alquilo C0-4, cicloalquilo C3-7-alquilo C0-4, cicloalquilo espirocíclico C3-7, amino-sulfonilo, y mono- y di-alquilo C1-6-amino-sulfonilo; m es 0, 1, o 2; n es 0, 1, 2, o 3; E está ausente, o es O o NR18: R11, R12, y R18 son iguales o diferentes, y se seleccionan independientemente en cada presentación a partir del grupo que consiste en hidrógeno y alquilo C1-4; y R13, R14, R15, R16 y R17 se seleccionan independientemente en cada presentación a partir del grupo que consiste en hidrógeno, alquilo C1-6, alcanoílo C1-6, cicloalquilo C3-6, fenilo y heterociclo, cada uno de los cuales está sustituido con 0, 1 o 2 residuos seleccionados independientemente a partir de alquilo C1-4, alcoxilo C1-4, halógeno, hidroxilo, amino, y mono- y di-alquilo C1-6-amino.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20124308P | 2008-12-09 | 2008-12-09 | |
| US23334109P | 2009-08-12 | 2009-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR074499A1 true AR074499A1 (es) | 2011-01-19 |
Family
ID=42034535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104731A AR074499A1 (es) | 2008-12-09 | 2009-12-07 | Carboxamidas heterobiciclicas como inhibidoras de cinasas |
Country Status (39)
| Country | Link |
|---|---|
| US (6) | US8242125B2 (es) |
| EP (1) | EP2376478B1 (es) |
| JP (1) | JP5580330B2 (es) |
| KR (1) | KR101345956B1 (es) |
| CN (2) | CN102307870B (es) |
| AR (1) | AR074499A1 (es) |
| AU (1) | AU2009326110B9 (es) |
| BR (1) | BRPI0922552A2 (es) |
| CA (1) | CA2745922C (es) |
| CL (1) | CL2011001378A1 (es) |
| CO (1) | CO6382119A2 (es) |
| CR (1) | CR20110270A (es) |
| CU (1) | CU24097B1 (es) |
| CY (1) | CY1119091T1 (es) |
| DK (1) | DK2376478T3 (es) |
| EA (1) | EA019681B1 (es) |
| EC (1) | ECSP11011113A (es) |
| ES (1) | ES2633959T3 (es) |
| HN (1) | HN2011001593A (es) |
| HR (1) | HRP20171075T1 (es) |
| HU (1) | HUE035292T2 (es) |
| IL (1) | IL213068A (es) |
| JO (1) | JO3265B1 (es) |
| LT (1) | LT2376478T (es) |
| MX (1) | MX2011006093A (es) |
| MY (1) | MY155649A (es) |
| NZ (2) | NZ593030A (es) |
| PE (1) | PE20110835A1 (es) |
| PL (1) | PL2376478T3 (es) |
| PT (1) | PT2376478T (es) |
| RS (1) | RS56076B1 (es) |
| SG (1) | SG171784A1 (es) |
| SI (1) | SI2376478T1 (es) |
| SV (1) | SV2011003939A (es) |
| TN (1) | TN2011000263A1 (es) |
| TW (1) | TWI429640B (es) |
| UY (1) | UY32302A (es) |
| WO (1) | WO2010066684A2 (es) |
| ZA (1) | ZA201103759B (es) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2350075E (pt) | 2008-09-22 | 2014-06-09 | Array Biopharma Inc | Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| ES2547145T3 (es) * | 2010-10-27 | 2015-10-02 | Novartis Ag | Regímenes de dosificación para el tratamiento de enfermedad vascular ocular |
| CN102786469B (zh) * | 2011-05-18 | 2016-09-14 | 中国医学科学院药物研究所 | 邻吡啶酰肼衍生物及其制法和药物组合物与用途 |
| US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| KR20150003903A (ko) * | 2012-05-04 | 2015-01-09 | 노파르티스 아게 | 보체 경로 조절제 및 그의 용도 |
| KR101315227B1 (ko) * | 2012-05-30 | 2013-10-07 | 엘지디스플레이 주식회사 | 터치스크린 일체형 표시장치 및 그 구동 방법 |
| US9815819B2 (en) * | 2012-06-28 | 2017-11-14 | Novartis Ag | Complement pathway modulators and uses thereof |
| US9388199B2 (en) * | 2012-06-28 | 2016-07-12 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| US9468661B2 (en) * | 2012-06-28 | 2016-10-18 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| CN104640855B (zh) * | 2012-06-28 | 2017-08-29 | 诺华股份有限公司 | 补体途经调节剂及其用途 |
| CN104379579B (zh) * | 2012-06-28 | 2017-03-08 | 诺华股份有限公司 | 吡咯烷衍生物及其作为补体途径调节剂的用途 |
| EA201590118A1 (ru) * | 2012-06-28 | 2015-04-30 | Новартис Аг | Производные пирролидина и их применение в качестве модуляторов пути активации комплемента |
| WO2014009833A2 (en) * | 2012-07-12 | 2014-01-16 | Novartis Ag | Complement pathway modulators and uses thereof |
| CN103570616B (zh) * | 2012-07-18 | 2017-10-20 | 中国医学科学院药物研究所 | N′‑直链烷酰基邻吡啶酰肼衍生物及其制法和药物组合物与用途 |
| WO2014143638A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 2-(1h-indol-4-ylmethyl)-3h-imidazo[4,5-b]pyridine-6-carbonitrile derivatives as complement factor b inhibitors useful for the treatment of ophthalmic diseases |
| CN104072481B (zh) * | 2013-03-28 | 2016-08-17 | 宁波市方昌医药有限公司 | 一种抗血管新生化合物 |
| US20150018376A1 (en) | 2013-05-17 | 2015-01-15 | Novartis Ag | Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof |
| US10174006B2 (en) * | 2013-06-06 | 2019-01-08 | Novartis Ag | Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| US9771351B2 (en) | 2013-07-29 | 2017-09-26 | Kyowa Hakko Kirin Co., Ltd. | Wnt signaling inhibitor |
| JP2016535042A (ja) * | 2013-10-30 | 2016-11-10 | ノバルティス アーゲー | ２−ベンジル−ベンゾイミダゾール補体因子ｂ阻害剤およびその使用 |
| US20160351119A1 (en) * | 2014-02-06 | 2016-12-01 | Joled Inc. | Display apparatus |
| JP2017206437A (ja) * | 2014-08-18 | 2017-11-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ４−アミノピリジン誘導体 |
| RU2701188C2 (ru) * | 2015-02-27 | 2019-09-25 | Нэнтбайосайенс, Инк. | Производные пиримидина в качестве ингибиторов киназы и их терапевтические применения |
| JP2018519292A (ja) * | 2015-07-01 | 2018-07-19 | ファーマケア，インク． | リシルオキシダーゼ様２阻害剤およびその使用 |
| JP6816100B2 (ja) | 2015-07-16 | 2021-01-20 | アレイ バイオファーマ、インコーポレイテッド | ＲＥＴキナーゼ阻害物質としての置換ピラゾロ［１，５−ａ］ピリジン化合物 |
| AU2016344058A1 (en) | 2015-10-26 | 2018-05-17 | Array Biopharma Inc. | Point mutations in Trk inhibitor-resistant cancer and methods relating to the same |
| EP3371170B1 (en) | 2015-11-06 | 2019-07-31 | H. Hoffnabb-La Roche Ag | Indolin-2-one derivatives useful in the treatment of cns diseases |
| JP6857653B2 (ja) | 2015-11-06 | 2021-04-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体 |
| EP3371174B1 (en) | 2015-11-06 | 2021-03-17 | H. Hoffnabb-La Roche Ag | Indolin-2-one derivatives |
| DK3371168T3 (da) | 2015-11-06 | 2020-08-03 | Hoffmann La Roche | Indolin-2-on-derivater |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| SG11201808676RA (en) | 2016-04-04 | 2018-11-29 | Loxo Oncology Inc | Methods of treating pediatric cancers |
| AU2017246554B2 (en) | 2016-04-04 | 2022-08-18 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| CA3024603A1 (en) | 2016-05-18 | 2017-11-23 | Charles Todd Eary | Process for the preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| EP3525819A1 (en) | 2016-10-14 | 2019-08-21 | Novartis AG | Methods for treating ocular disease using inhibitors of csf-1r |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| CN110267960B (zh) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| TW202410896A (zh) | 2017-10-10 | 2024-03-16 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| US11603374B2 (en) | 2018-01-18 | 2023-03-14 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| EP3740490A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| EP3740486A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors |
| CN108586454B (zh) * | 2018-02-13 | 2021-02-26 | 沈阳药科大学 | 四氢吡啶并[4,3-d]嘧啶类衍生物及其用途 |
| CN110386892B (zh) * | 2018-04-16 | 2020-08-18 | 新发药业有限公司 | 一种4-氟-5-羟基-2-甲基-1h-吲哚的制备方法 |
| CN110483482A (zh) * | 2018-05-15 | 2019-11-22 | 北京诺诚健华医药科技有限公司 | 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用 |
| US20210330643A1 (en) | 2018-07-31 | 2021-10-28 | Loxo Oncology, Inc. | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide |
| CN112996794A (zh) | 2018-09-10 | 2021-06-18 | 阿雷生物药品公司 | 作为ret激酶抑制剂的稠合杂环化合物 |
| JP2022515197A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体 |
| CN113490666A (zh) | 2018-12-19 | 2021-10-08 | 奥瑞生物药品公司 | 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物 |
| JP2023509886A (ja) | 2019-12-27 | 2023-03-10 | シュレーディンガー， インコーポレイテッド | 環式化合物およびその使用方法 |
| WO2022033472A1 (zh) * | 2020-08-11 | 2022-02-17 | 河南迈英诺医药科技有限公司 | Fgfr抑制剂化合物及其用途 |
| JP2023541047A (ja) | 2020-09-10 | 2023-09-27 | シュレーディンガー， インコーポレイテッド | がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤 |
| JP2024505890A (ja) | 2021-01-26 | 2024-02-08 | シュレーディンガー， インコーポレイテッド | がん、自己免疫及び炎症性障害の治療に有用な三環式化合物 |
| TW202300150A (zh) | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| IL314186A (en) | 2022-01-24 | 2024-09-01 | Novartis Ag | PIPERIDINYL SPIROCYCLIC DERIVATIVES AS COMPLEMENT B FACTOR INHIBITORS AND USES THEREOF |
| WO2023187715A1 (en) | 2022-04-01 | 2023-10-05 | Novartis Ag | Complement factor b inhibitors and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1254138B1 (en) | 2000-02-09 | 2005-05-11 | Novartis AG | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
| ATE355275T1 (de) * | 2000-10-20 | 2006-03-15 | Eisai R&D Man Co Ltd | Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen |
| GB0126902D0 (en) | 2001-11-08 | 2002-01-02 | Novartis Ag | Organic compounds |
| PE20040522A1 (es) * | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| NZ538617A (en) * | 2002-08-30 | 2005-12-23 | Eisai Co Ltd | Azaarene derivatives |
| TW200418466A (en) * | 2002-11-06 | 2004-10-01 | Smithkline Beecham Corp | Chemical compounds |
| SE0302324D0 (sv) | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| PE20060664A1 (es) * | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
| GB0420520D0 (en) * | 2004-09-15 | 2004-10-20 | Novartis Ag | Organic compounds |
| GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
| GT200600411A (es) * | 2005-09-13 | 2007-05-21 | Novartis Ag | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular |
| EP2574340A3 (en) | 2006-04-07 | 2013-04-17 | Novartis AG | Combination comprising a pyrimidylaminobenzamide compound and a THR315LLEe kinase inhibitor |
| JP2010535773A (ja) | 2007-08-10 | 2010-11-25 | グラクソスミスクライン エルエルシー | ウイルス感染を治療するための窒素含有二環式化学物質 |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| TWI440638B (zh) | 2007-10-30 | 2014-06-11 | Otsuka Pharma Co Ltd | 雜環化合物及其藥學組成物 |
-
2009
- 2009-12-06 JO JOP/2009/0466A patent/JO3265B1/ar active
- 2009-12-07 EA EA201100873A patent/EA019681B1/ru not_active IP Right Cessation
- 2009-12-07 RS RS20170576A patent/RS56076B1/sr unknown
- 2009-12-07 UY UY0001032302A patent/UY32302A/es not_active Application Discontinuation
- 2009-12-07 MY MYPI2011002414A patent/MY155649A/en unknown
- 2009-12-07 WO PCT/EP2009/066540 patent/WO2010066684A2/en active Application Filing
- 2009-12-07 NZ NZ593030A patent/NZ593030A/xx not_active IP Right Cessation
- 2009-12-07 CU CU2011000129A patent/CU24097B1/es active IP Right Grant
- 2009-12-07 DK DK09774876.8T patent/DK2376478T3/en active
- 2009-12-07 LT LTEP09774876.8T patent/LT2376478T/lt unknown
- 2009-12-07 PL PL09774876T patent/PL2376478T3/pl unknown
- 2009-12-07 MX MX2011006093A patent/MX2011006093A/es active IP Right Grant
- 2009-12-07 NZ NZ601656A patent/NZ601656A/xx not_active IP Right Cessation
- 2009-12-07 CN CN200980156323.7A patent/CN102307870B/zh active Active
- 2009-12-07 AR ARP090104731A patent/AR074499A1/es unknown
- 2009-12-07 KR KR1020117015822A patent/KR101345956B1/ko active IP Right Grant
- 2009-12-07 PT PT97748768T patent/PT2376478T/pt unknown
- 2009-12-07 EP EP09774876.8A patent/EP2376478B1/en active Active
- 2009-12-07 CA CA2745922A patent/CA2745922C/en not_active Expired - Fee Related
- 2009-12-07 JP JP2011540046A patent/JP5580330B2/ja active Active
- 2009-12-07 SG SG2011036878A patent/SG171784A1/en unknown
- 2009-12-07 HU HUE09774876A patent/HUE035292T2/en unknown
- 2009-12-07 BR BRPI0922552A patent/BRPI0922552A2/pt not_active IP Right Cessation
- 2009-12-07 CN CN201310101393.0A patent/CN103193773B/zh active Active
- 2009-12-07 US US12/632,396 patent/US8242125B2/en active Active
- 2009-12-07 SI SI200931684A patent/SI2376478T1/sl unknown
- 2009-12-07 PE PE2011001180A patent/PE20110835A1/es not_active Application Discontinuation
- 2009-12-07 ES ES09774876.8T patent/ES2633959T3/es active Active
- 2009-12-07 AU AU2009326110A patent/AU2009326110B9/en not_active Ceased
- 2009-12-08 TW TW098141904A patent/TWI429640B/zh not_active IP Right Cessation
-
2011
- 2011-05-23 IL IL213068A patent/IL213068A/en not_active IP Right Cessation
- 2011-05-23 TN TN2011000263A patent/TN2011000263A1/fr unknown
- 2011-05-23 ZA ZA2011/03759A patent/ZA201103759B/en unknown
- 2011-05-23 CR CR20110270A patent/CR20110270A/es unknown
- 2011-06-07 EC EC2011011113A patent/ECSP11011113A/es unknown
- 2011-06-08 CL CL2011001378A patent/CL2011001378A1/es unknown
- 2011-06-09 HN HN2011001593A patent/HN2011001593A/es unknown
- 2011-06-09 SV SV2011003939A patent/SV2011003939A/es unknown
- 2011-06-10 CO CO11072268A patent/CO6382119A2/es active IP Right Grant
-
2012
- 2012-06-05 US US13/488,760 patent/US8431584B2/en active Active
- 2012-09-13 US US13/613,034 patent/US8486954B2/en active Active
- 2012-09-13 US US13/613,019 patent/US8492393B2/en active Active
- 2012-09-13 US US13/613,062 patent/US8501756B2/en active Active
- 2012-09-13 US US13/613,053 patent/US8541432B2/en active Active
-
2017
- 2017-07-12 HR HRP20171075TT patent/HRP20171075T1/hr unknown
- 2017-07-19 CY CY20171100772T patent/CY1119091T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR074499A1 (es) | Carboxamidas heterobiciclicas como inhibidoras de cinasas | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
| AR112216A1 (es) | Derivados de azaquinolina | |
| AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
| AR079689A1 (es) | Derivados de imidazo[1,2a]piridina, composiciones farmaceuticas que los comprenden y uso de los mismos en trastornos mieloproliferativos, leucemia y enfermedades inmunologicas e inflamatorias. | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| PE20170003A1 (es) | Compuestos heterociclicos y usos de los mismos | |
| AR095311A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante | |
| ES2570127T3 (es) | Compuestos y composiciones como inhibidores de la proteína quinasa | |
| AR087348A1 (es) | Indazoles, composiciones farmaceuticas que comprenden tales compuestos y su uso como medicamentos | |
| AR062785A1 (es) | Compuestos de 4-metilpiridopirimidinona, composiciones farmaceuticas que los contienen y usos en estados patologicos asociados al crecimiento anormal celular,tal como cancer. | |
| AR090548A1 (es) | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k | |
| AR074543A1 (es) | Derivados de imidazo[1,2-a]piridin-2-il, agonistas de receptores 1-fosfato de esfingosina(1s1p1), composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes | |
| AR076860A1 (es) | Derivados de 7-aril- 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
| AR088352A1 (es) | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina | |
| AR087841A1 (es) | Derivados de tetrahidrotriazolopirimidina | |
| AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
| AR090005A1 (es) | Imidazo[1,2-a]pirimidinas y piridinas sustituidas | |
| AR071300A1 (es) | Compuestos; composiciones farmaceuticas en base al compuesto y uso del mismo para la manufactura de un medicamento | |
| PE20061362A1 (es) | Derivados de tetrahidronaftalina, procedimientos para su preparacion y su uso como inhibidor de la inflamacion | |
| AR073262A1 (es) | Derivados de pirazolo[5, 1-b]oxazol, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por antagonistas de crf1. | |
| AR087563A1 (es) | Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |